U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C7H8ClN3O4S2
Molecular Weight 297.739
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCHLOROTHIAZIDE

SMILES

NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1

InChI

InChIKey=JZUFKLXOESDKRF-UHFFFAOYSA-N
InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

HIDE SMILES / InChI
Molecular Formula C7H8ClN3O4S2
Molecular Weight 297.739
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

1959
143
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 70.0 µM [IC50]
Inhibitor
8504
 117.0 µM [IC50]
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
490 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020504s018lbl.pdf
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
70 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020504s018lbl.pdf
12.5 mg 1 times / day steady-state, oral
dose: 12.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
142.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11112088/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1032.22 ng/mL
EXPERIMENT
https://japsonline.com/abstract.php?article_id=2146&sts=2
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
164 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3034318/
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
210 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3034318/
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
954.44 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11112088/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3615.08 ng × h/mL
EXPERIMENT
https://japsonline.com/abstract.php?article_id=2146&sts=2
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1629 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3034318/
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1760 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3034318/
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.8 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020504s018lbl.pdf
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
8.57 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11112088/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3034318/
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.5 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3034318/
25 mg 1 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: CAPTOPRIL
CAPTOPRIL
 HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
46%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020504s018lbl.pdf
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCHLOROTHIAZIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
56%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26142561/
HYDROCHLOROTHIAZIDE serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10423601
unhealthy, 55.5
Health Status: unhealthy
Age Group: 55.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10423601
Disc. AE: Fatigue, Hypokalemia...
AEs leading to
discontinuation/dose reduction:
Fatigue (1.12%)
Hypokalemia (1.12%)
Dry mouth (1.12%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10423601
100 mg single, oral
Recommended
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf
Disc. AE: Acute myopia, Angle closure glaucoma...
AEs leading to
discontinuation/dose reduction:
Acute myopia
Angle closure glaucoma
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
Disc. AE: Acute myopia, Angle closure glaucoma...
AEs leading to
discontinuation/dose reduction:
Acute myopia
Angle closure glaucoma
Diabetes
Hypoglycemia
Renal disease
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
AEs

AEs

AESignificanceDosePopulation
Dry mouth 1.12%
Disc. AE
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10423601
unhealthy, 55.5
Health Status: unhealthy
Age Group: 55.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10423601
Fatigue 1.12%
Disc. AE
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10423601
unhealthy, 55.5
Health Status: unhealthy
Age Group: 55.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10423601
Hypokalemia 1.12%
Disc. AE
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10423601
unhealthy, 55.5
Health Status: unhealthy
Age Group: 55.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10423601
Acute myopia Disc. AE
100 mg single, oral
Recommended
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf
Angle closure glaucoma Disc. AE
100 mg single, oral
Recommended
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf
Acute myopia Disc. AE
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
Angle closure glaucoma Disc. AE
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
Diabetes Disc. AE
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
Hypoglycemia Disc. AE
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
Renal disease Disc. AE
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
unhealthy
Health Status: unhealthy
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OAT3
747

OAT1
725

OAT2
153
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OAT2
155
 yes [IC50 1023 uM]
OAT1
730
 yes [IC50 67.3 uM]
OAT3
749
 yes [IC50 942 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5778
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5778
ChemicalBook
CB31564779
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB31564779
ChemicalBook
CB5383966
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5383966
eMolecules
539058
https://www.emolecules.com/cgi-bin/more?vid=539058
MolPort
MolPort-000-144-465
https://www.molport.com/shop/molecule-link/MolPort-000-144-465
Selleck Chemicals
Hydrochlorothiazide
http://www.selleckchem.com/products/Hydrochlorothiazide.html
ZINC
ZINC000000896569
http://zinc15.docking.org/substances/ZINC000000896569
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:53:04 GMT 2025
Edited
by admin
on Mon Mar 31 17:53:04 GMT 2025
Record UNII
0J48LPH2TH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCHLOROTHIAZIDE
EMA EPAR   EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
ACCURETIC COMPONENT HYDROCHLOROTHIAZIDE
Preferred Name English
ORETICYL FORTE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HYDROCHLOROTHIAZIDE [IARC]
Common Name English
SER-A-GEN COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
SU-5879
Code English
CAROZIDE
Common Name English
UNIPRES COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
ZIAC
Brand Name English
HYDRO-D
Brand Name English
NSC-53477
Code English
MICROZIDE
Brand Name English
ZIDE
Brand Name English
IMPRIDA-HCT
Brand Name English
HYDRO-RESERP COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HYDROCHLOROTHIAZIDE [ORANGE BOOK]
Common Name English
ALDACTAZIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
IDROTIAZIDE
Brand Name English
PANTEMON
Brand Name English
DAFIRO-HCT
Brand Name English
HYDROCHLOROTHIAZIDE [USP-RS]
Common Name English
SERPASIL-ESIDRIX COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
IFIRMACOMBI COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
ZIAC COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
KINZALKOMB COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
AVALIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
PRITORPLUS COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
MODURETIC COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
TRIBENZOR COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
HYDRODIURIL
Brand Name English
HYDROCHLOROTHIAZIDE [JAN]
Common Name English
HYDROCHLOROTHIAZIDE [MART.]
Common Name English
ORETIC
Brand Name English
ESIDREX
Brand Name English
HYDROCHLOROTHIAZIDE COMPONENT
Brand Name English
TEKTURNA HCT COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
Systematic Name English
RIPRAZO COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
HYDROCHLOROTHIAZIDE [EP MONOGRAPH]
Common Name English
SERVITHIAZID
Common Name English
HYDROCHLOROTHIAZIDE [GREEN BOOK]
Common Name English
HYDROCHLOROTHIAZIDE [WHO-IP]
Common Name English
AMTURNIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HYDROCHLOROTHIAIZIDE
Brand Name English
HYDRAP-ES COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
LOTENSIN HCT COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
NORMOZIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
BENICAR HCT COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HCTZ
Common Name English
VASERETIC COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
MEGADIURIL
Common Name English
VISKAZIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
DYAZIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
Hydrochlorothiazide [WHO-DD]
Common Name English
APRESOLINE-ESIDRIX COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
hydrochlorothiazide [INN]
Common Name English
CHLOROSULTHIADIL
Common Name English
MONOPRIL HCT COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
SPRIMEO-HCT COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
HYDROCHLOROTHIAZIDE [VANDF]
Common Name English
HYDROCHLOROTHIAZIDE [MI]
Common Name English
HYDRA-ZIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
ESIDRIX
Brand Name English
RASITRIO COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
HYZAAR COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
TEVETEN HCT COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
CAM-AP-ES COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
MAXZIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
ESIMIL COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
SER-AP-ES COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
QUINARETIC COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE, 6-CHLORO-3,4-DIHYDRO-, 1,1-DIOXIDE
Systematic Name English
DUTOPROL COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
RASILEZ-HCT
Brand Name English
VETIDREX
Brand Name English
POLYCAP COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
UNIPRES
Common Name English
KERVEZIDE COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
MICARDIS HCT COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
LOPRESSOR HCT COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HYDROCHLOROTHIAZIDE [HSDB]
Common Name English
PRINZIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
UNIRETIC COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
APRESAZIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HYDROCHLOROTHIAZIDE [USP MONOGRAPH]
Common Name English
IRBESARTAN/HYDROCHLOROTHIAZIDE TEVA COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
APRESAZIDE
Brand Name English
HYDRO-RIDE COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
DIHYDROCHLORURITE
Common Name English
DIOVAN HCT COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HCT
Common Name English
HYDROSERPINE PLUS (R-H-H) COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HH-50/50
Common Name English
H.R.-50 COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
ZESTORETIC COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HYDROPRES COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HYDROCHLOROTHIAZIDE [EP IMPURITY]
Common Name English
HYDROCHLOROTHIAZIDE [EMA EPAR]
Common Name English
IRBESARTAN/HYDROCHLOROTHIAZIDE-BMS COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
LOTENSIN HCT
Common Name English
MICARDISPLUS COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
EXFORGE HCT COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
COPALIA-HCT
Brand Name English
ALDORIL COMPONENT HYDROCHLOROTHIAZIDE
Common Name English
HYDROCHLOROTHIAZIDUM [WHO-IP LATIN]
Common Name English
HIDROTIAZIDA
Brand Name English
NEWTOLIDE
Common Name English
EXFORGE-HCT
Brand Name English
INZIRQO
Brand Name English
TOLUCOMBI COMPONENT HYDROCHLOROTHIAZIDE
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS RASITRIO (WITHDRAWN: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
EMA ASSESSMENT REPORTS TOLUCOMBI (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
EMA ASSESSMENT REPORTS IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-ATC C03AB03
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
EMA ASSESSMENT REPORTS IBERSARTAN/HYDROCHLOROTHIAZIDE-BMS (WITHDRAWN: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
NDF-RT N0000166469
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
WHO-VATC QC09DX01
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
EMA ASSESSMENT REPORTS SPRIMEO-HCT (WITHDRAWN: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
EMA ASSESSMENT REPORTS EXFORGE-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-VATC QC09DX03
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
EMA ASSESSMENT REPORTS KINZALKOMB (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
EMA ASSESSMENT REPORTS KARVEZIDE (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-ATC C09XA52
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
EMA ASSESSMENT REPORTS RASILEZ-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 12.3
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
IARC Hydrochlorothiazide
EMA ASSESSMENT REPORTS IMPRIDA-HCT (WITHDRAWN: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
EMA ASSESSMENT REPORTS MICARDISPLUS (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-ATC C03AA03
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
WHO-VATC QC03EA01
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
EMA ASSESSMENT REPORTS PRITORPLUS (AUTHORIZED: HYPERTENSION0
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-ATC C09XA54
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
WHO-VATC QC03AA03
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
WHO-ATC C03EA01
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
WHO-ATC C09DX01
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
WHO-ATC C09BX03
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
NDF-RT N0000175419
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
WHO-VATC QC09XA52
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
EMA ASSESSMENT REPORTS RIPRAZO-HCT (WITHDRAWN: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 12.4
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
WHO-VATC QC03AX01
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
LIVERTOX 483
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
EMA ASSESSMENT REPORTS IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 16
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
NDF-RT N0000175359
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
EMA ASSESSMENT REPORTS COPALIA-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-VATC QC09XA54
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
EMA ASSESSMENT REPORTS IFIRMACOMBI (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-VATC QC03AB03
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
CFR 21 CFR 522.1150
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
WHO-ATC C09DX03
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
NDF-RT N0000166469
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
NCI_THESAURUS C49185
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
EMA ASSESSMENT REPORTS DAFIRO-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-ATC C09DX06
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
WHO-ATC C03AX01
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
Code System Code Type Description
CAS
8049-49-8
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
SUPERSEDED
DRUG BANK
DB00999
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
WIKIPEDIA
HYDROCHLOROTHIAZIDE
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
PRIMARY
RXCUI
5487
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID2020713
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
HYDROCHLOROTHIAZIDE
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Very slightly soluble in water; practically insoluble in ether R; soluble in 200 parts of ethanol (~750 g/l) TS and in 20 parts of acetone R. Category: Diuretic. Storage: Hydrochlorothiazide should be kept in a well-closed container. Definition: Hydrochlorothiazide contains not less than 98.0% and not more than 102.0% of C7H8ClN3O4S2, calculated with reference to the dried substance.
HSDB
3096
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
CAS
58-93-5
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
PRIMARY
RS_ITEM_NUM
1314009
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
SMS_ID
100000091737
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
NCI_THESAURUS
C29098
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
PRIMARY
FDA UNII
0J48LPH2TH
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
NSC
53477
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
MESH
D006852
Created by admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
PRIMARY
MERCK INDEX
m6089
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY Merck Index
INN
841
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
EVMPD
SUB08062MIG
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
LACTMED
Hydrochlorothiazide
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
PUBCHEM
3639
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
DAILYMED
0J48LPH2TH
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-403-3
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
ChEMBL
CHEMBL435
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
DRUG CENTRAL
1385
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
IUPHAR
4836
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
CHEBI
5778
Created by admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
PRIMARY
Related Record Type Details
Structure of HYDROCHLOROTHIAZIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
OAT-1
TRANSPORTER -> INHIBITOR
Structure of HYDROCHLOROTHIAZIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of HYDROCHLOROTHIAZIDE
EXCRETED UNCHANGED
URINE
OAT-3
TRANSPORTER -> INHIBITOR
OAT-2
TRANSPORTER -> INHIBITOR
SOLUTE CARRIER FAMILY 12 MEMBER 3
TARGET -> INHIBITOR
Structure of CHLORAMINOPHENAMIDE
DERIVATIVE -> PARENT
Structure of HYDROCHLOROTHIAZIDE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of CHLORAMINOPHENAMIDE
METABOLITE -> PARENT
Related Record Type Details
Structure of 6-CHLORO-N-((6-CHLORO-7-SULFAMOYL-2,3-DIHYDRO-4H-1,2,4-BENZOTHIADIAZIN-4-YL 1,1-DIOXIDE)METHYL)-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-nitroso-hydrochlorothiazide
IMPURITY -> PARENT
Structure of CHLOROTHIAZIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of CHLOROTHIAZIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6-CHLORO-N-((6-CHLORO-7-SULFAMOYL-2,3-DIHYDRO-4H-1,2,4-BENZOTHIADIAZIN-4-YL 1,1-DIOXIDE)METHYL)-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of CHLORAMINOPHENAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of CHLORAMINOPHENAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5-CHLOROHYDROCHLOROTHIAZIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of HYDROCHLOROTHIAZIDE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966